Company intelligence / Profile preview
Rivopharm
Manno, Ticino, Switzerland
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
Rivopharm develops, manufactures and globally supplies generic small‑molecule pharmaceutical products across multiple therapeutic areas, including launches such as generic nicorandil, lacidipine, racecadotril and mexiletine, and has US FDA‑inspected cGMP manufacturing and ANDA approvals enabling commercial sales in the US and more than 50 other countries.[1][3][4][7]
- Therapeutic areas
- ImmunologyEndocrinologyCardiovascularNeurologyInfectious DiseasesGastroenterologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lannett (US commercialization partner for mexiletine hydrochloride capsules, generic equivalent of Mexitil)[3]
Beyond the preview
Go deeper on Rivopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rivopharm.